论文部分内容阅读
目的探讨2型糖尿病(T2DM)患者尿Nephrin排泄的变化以及吡格列酮干预对其的影响。方法将98例T2DM患者随机分为磺脲类药物干预组(DS组)、吡格列酮干预组(DP组),观察治疗前后相关代谢指标及尿Nephrin排泄的变化,选择同期健康体检人群49名为正常对照(NC)组。结果 DP组、DS组患者FPG、HbA_1c、尿白蛋白(UAlb)/尿肌酐(UCr)比值较NC组明显升高(P<0.01)。NC组尿中未检测到Nephrin;DP组干预后尿Nephrin/UCr比值明显下降(P<0.01),DS组干预前后尿Nephrin/UCr比值的差异无统计学意义(P>0.05)。结论吡格列酮可降低T2DM患者尿Nephrin排泄,对肾小球足细胞有保护作用。
Objective To investigate the change of urinary Nephrin excretion in type 2 diabetic patients and the effect of pioglitazone on it. Methods Ninety-two T2DM patients were randomly divided into four groups: the sulfonylurea intervention group (DS group) and the pioglitazone intervention group (DP group). The changes of the metabolic index and urinary Nephrin excretion before and after treatment were observed. Forty-nine healthy subjects Control (NC) group. Results The ratio of FPG, HbA 1c, UAb / UCr in DP group and DS group was significantly higher than that in NC group (P <0.01). No Nephrin was detected in urine of NC group; Nephrin / UCr ratio of urine in DP group was significantly decreased (P <0.01), but there was no significant difference in urinary Nephrin / UCr before and after DS group (P> 0.05). Conclusion Pioglitazone can reduce urinary Nephrin excretion in T2DM patients and protect glomerular podocytes.